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There has been intense media publicity for cancer genetic dis-
coveries, especially those relating to breast cancer (BRCA1 and
BRCA2), resulting in an increased public demand for information,
reassurance and cancer screening. 
In the UK, most regionally based clinical genetics centres now
provide genetics clinics that are specifically for familial cancers.
These services often involve collaboration between clinical geneti-
cists, oncologists and other specialists. They have developed in a
variety of ways according to local expertise and funding. In addi-
tion, a number of other family history clinics have been set up by
other clinicians, such as breast surgeons, with variable levels of
training in clinical genetics. A cancer genetics service will offer or
recommend some of the following: risk estimation (based on
molecular genetic analysis or more often on family history);
genetic risk counselling; clinical examination; screening/surveil-
lance for early tumour detection (mammography, endoscopy, etc);
information on preventative strategies (surgery, diet, etc); family
planning advice; and referral for psychological assessment/support
(Murday, 1994; Ponder, 1994; Eeles and Murday, 1996). 
In 1996, the Department of Health set up a working group on
cancer genetics services chaired by Professor Peter Harper. The
Harper report (Working Group for the Chief Medical Officer, 1998)
recommended organization of cancer genetic services for England
and Wales in a 3-tier structure integrated with the developing 3-tier
cancer service that followed the Calman-Hine Report (Expert
Advisory Group on Cancer, 1995). First, the role of primary care
would be to refer on individuals newly identified as being at poten-
tially high genetic risk of cancer, to follow-up existing high-risk
individuals and to reassure individuals at population-level risk.
Second, cancer units (based at district general hospitals) staffed by
oncologists and surgeons with an interest in genetics, would
provide risk assessment and, if appropriate, screening for individ-
uals at moderately increased risk. Third, specialist genetics services
would be integrated into the specialist cancer centre, serving a
population of 1–2 million. This specialist service would be led by a
consultant with training in both oncology and genetics, supported
by 2 clinical nurse specialists (or one nurse and one clinical assis-
tant). The specialist service would deal with high-risk individuals
and would provide referral and management guidelines for the
primary care and cancer unit teams within its region. The Harper
report forms the basis of the NHS Cancer Plan’s framework for
cancer genetics services (NHS Executive, 2000). 
An alternative service organization model has been proposed
for Scotland (Priority Areas Cancer Team, 1998). Unlike the
Calman-Hine scheme, there is no second tier. Instead staff from
the regional genetics service would support staff in surveillance
units and in primary care facilities by carrying out genetic coun-
selling in outreach clinics. The service in Northern Ireland is
modelled on the Calman-Hine system (Morrison and Nevin,
1999), but is developing centralized referrals mechanism, along
the lines of the Scottish services. 
Following the identification of cancer-predisposing genes,
the national picture of cancer genetics service activity has been
unclear. Reported in this paper are the results of a cross-sectional
study conducted in 1998 showing the pattern of cancer genetics
services across the NHS. 
A descriptive study of UK cancer genetics services: an
emerging clinical response to the new genetics 
D Wonderling1, P Hopwood2, A Cull3, F Douglas4, M Watson5, J Burn4 and K McPherson1
1Cancer and Public Health Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT; 2The Cancer Research Campaign
Psychological Medicine Group, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, M20 4BX; 3Imperial Cancer Research Fund, Psychology
Group, Western General Hospital, Outpatient Building, Edinburgh, EH4 2XU; 4Department of Medical Genetics, Regional Genetics Service, 19/29 Claremont
Place, Newcastle-upon-Tyne, NE2 4AA; 5Psychological Medicine, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, Sutton, Surrey,
SM2 5PT 
Summary The objective was to describe NHS cancer genetic counselling services and compare UK regions. The study design was a cross-
sectional study over 4 weeks and attendee survey. The setting was 22 of the 24 regional cancer genetics services in the UK NHS. Participants
were individuals aged over 18 attending clinics at these services. Outcome measures were staff levels, referral rates, consultation rates, follow-up
plans, waiting time. There were only 11 dedicated cancer geneticists across the 22 centres. Referrals were mainly concerned with breast (63%),
bowel (18%) and ovarian (12%) cancers. Only 7% of referrals were for men and 3% were for individuals from ethnic minorities. Referral rates
varied from 76 to 410 per million per annum across the regions. Median waiting time for an initial appointment was 19 weeks, ranging across
regions from 4 to 53 weeks. Individuals at population-level genetic risk accounted for 27% of consultations (range 0%, 58%). Shortfalls in cancer
genetics staff and in the provision of genetic testing and cancer surveillance have resulted in large regional variations in access to care. Initiatives
to disseminate referral and management guidelines to cancer units and primary care should be adequately resourced so that clinical genetics
teams can focus on the genetic testing and management of high-risk families. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: genetic counselling; cancer genetics services; health service organization; Calman-Hine 
166
Received 18 August 2000 
Revised 29 March 2001 
Accepted 5 April 2001 
Correspondence to: P Hopwood 
British Journal of Cancer (2001) 85(2), 166–170
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1893, available online at http://www.idealibrary.com on  http://www.bjcancer.comMETHODS 
All regional genetics services in the UK were invited to partici-
pate. Procedures were explained at a training workshop to help
ensure good compliance. Ethical approval was obtained through
the Multicentre Research Ethics Committee. 
During a pre-specified 4-week period cancer genetic activity in
all participating centres was logged. Designated staff-members at
each centre completed report forms for every referral received,
every individual attending, every telephone consultation and
every cancellation/did-not-attend. Only activity relating to
subjects under the age of 18 was excluded from the study.
Information was requested about types of cancer/syndrome,
source of and reason for referral, content of consulation and risk
management plan for the individual. In addition, the lead consul-
tant at each study centre was asked to supply general information
about their service, such as catchment population size, frequency
of clinics and details of staffing. Clinic attendees gave written
informed consent and were asked to complete a questionnaire to
provide mainly sociodemographic information. 
We tested to see if the variability observed between regions
could have occurred by chance. The Kruskal–Wallis test was used
for waiting time and c2 test for all other comparisons. 
RESULTS 
22 of 24 regional genetics services agreed to participate. The
catchment area of the participating centres covered the whole of
Scotland, Wales and Northern Ireland and most of England,
varying by region from 0.5 to 5.2 million population. These
regional genetics services see individuals with a family history of
cancer in a total of 141 hospitals. 53 of these hospitals held clinics
specifically for familial cancer. 58% of new-attendee consultations
were held in these designated cancer genetics clinics, 25% were in
general genetics clinics and the remaining 17% were in other
hospital clinics (e.g. breast lump diagnostic clinics). In the absence
of facilities specifically for cancer families, there were 2 regions
where all attendees were seen in general genetics clinics. In the
other 20 centres the number of designated cancer genetics clinics
provided per month ranged from 3 to 16 with a mean of 7.5. 
The regions also varied according to whether they provided
cancer screening (e.g. mammography) directly (3/22) or else
referred on or left the clinical management decision with the
general practitioner. There was also variability in the use of family
history questionnaires as part of the referral process. 7 centres sent
questionnaires to more than two thirds of referred individuals
before deciding whether to offer an appointment. One would
expect these centres to be seeing proportionately fewer people than
those centres with less restrictive appointment criteria. 
12 of the 22 lead clinicians from the centres were aware of other
cancer family history clinics within the region but outside of their
jurisdiction. They specified 13 such clinics organized by breast
screening units, 14 by breast surgeons and 2 by bowel surgeons,
although these may represent the tip of the iceberg. In Scotland
the clinicians reported that almost all family history clinics were
organized by the regional genetics service. 
Staffing of centres 
In total there were 17 whole-time equivalent (WTE) consultants
for a total catchment population of 53 million, consisting of 11
‘dedicated’ cancer genetics consultants (those spending more than
50% of their working time on cancer genetics) and another 46
consultants (mainly clinical geneticists) allocating less time. This
amounts to 0.3 WTE consultants, or 0.2 ‘dedicated’ consultants,
per million of population. There were another 5 ‘dedicated’ cancer
genetics clinicians below consultant grade and 33 genetic counsel-
lors (clinical nurse specialists, genetic associates, etc.). Therefore
only half of the centres had a ‘dedicated’ cancer genetics consul-
tant and 6 had no such dedicated staff at all, including the one with
the largest catchment population. 
Activity levels and case-mix 
Table 1 shows the activity levels of the 22 regional centres combined.
Referrals came equally from GPs (49%) and hospital clinicians
(47%) with a few self-referrals. Table 2 shows the breakdown of
referrals by gender and cancer site. The mean age of referrals was 41
years (SD = 11.5). Only 3% of attendees reported an ethnicity other
than ‘white’ and almost half of these were ‘Jewish’ (a group known
to be at greater genetic risk of breast cancer (Warner et al, 1999)). 
Of the new-attendee consultations, 17% of attendees had previ-
ously been diagnosed with cancer (i.e. were ‘affected’). Clinicians
were asked to assign new attendees to one of 3 risk level categories
– in some cases this was imprecise because the clinician was
waiting for additional information before making the final clinical
management decision. One quarter of clinic attendees (26%) were
categorized as ‘population level cancer risk or marginally above’.
49% were categorized as ‘risk level sufficient for screening’ and
the remaining 25% was placed in the highest risk category. 
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Table 1 Activity in 22 NHS cancer genetics services 
Number in 4  Estimated  Estimated number 
weeks number per per year per million 
year* population†
New-attendee consultations 694 8744 164 
Followup consultations 357 4498 84 
Home visits 74 932 17 
Telephone consultations 206 2596 49 
All contacts 1331 16771 315
Cancellations 98 1235 23 
Failed-to-attend 146 1840 35 
Referrals 872 10987 206 
*Assuming 252 clinic days per year (260 weekdays minus 8 public holidays). †Population = 53.3
million (90% of the UK). 168 D Wonderling et al 
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Risk management 
74% of attendees at marginal risk were to be discharged without
follow-up compared with only 12% and 5% in the middle and
upper risk categories respectively. 25% of the middle risk group
and 30% of the high-risk group would be referred on to another
specialist. Many of these onward referrals, 50%, were for
screening (mammography, clinical breast examination, endoscopy,
etc.), a few were clearly for prophylactic surgery (mastectomy,
colectomy, etc.) but for the rest it was not clear whether the referral
was for screening, surgery or some other purpose. Cancer
screening would be recommended for 97% of moderately
increased and high-risk individuals (continued for 47% and initi-
ated for 50%). For those at population risk 13% of familial breast
cancer cases and 44% of familial bowel cancer were already being
screened and for these the recommendation would be to discon-
tinue screening. Prophylactic surgery would be discussed with
30% of individuals estimated to be at high-risk of breast cancer
and 19% of those at high risk of bowel cancer. Clinicians indicated
that they would consider molecular genetic testing for 63% of
high-risk individuals and 24% of those at moderate risk. The
number of tests actually carried out would be much smaller
because of supply constraints and because many individuals
decide not to go ahead with testing after counselling (Peshkin and
Lerman, 1999). 
Regional variations 
Table 3 shows variations in activity between the regional cancer
genetics services. Referral rates per million population varied
significantly across the regions (P < 0.001) with a 5-fold differ-
ence at the extreme. Likewise, there was an 8-fold difference in the
number of consultations with new attendees per million population
across the region (P < 0.001). Referral rates were 53% higher in
those centres providing mammography directly (P < 0.001) and
75% higher in those centres with a ‘dedicated’ cancer genetics
consultant (P < 0.001). The 2 centres without familial cancer
clinics had a 24% lower referral rate (P < 0.043). Referral rates
were 40% higher in those centres with the most extensive use of
pre-appointment questionnaires (P < 0.001), but they saw only
73% of referrals compared with 90% in the other centres. The
proportion of a centre’s referrals coming from primary care varied
from 27% to 70% (P < 0.001). 
There was a 13-fold difference in median waiting time across
centres (range: 4–53 weeks; P < 0.001) (Table 3), but no significant
difference in waiting time between high-risk and population-risk
Table 2 Referrals, by cancer site and sex 
Referrals Male Female All 
Breast* 7 (1%) 526 (99%) 533   61% 
Bowel† 43 (32%) 93 (68%) 136   16% 
Breast and bowel 1 (5%) 18 (95%) 19     2% 
Ovary‡ 0 106 (100%) 106   12% 
Other specified§ 12 (24%) 37 (76%) 49     6% 
Not specified 1 (4%) 25 (96%) 26     3% 
All 64 (7%) 805 (93%) 869 100% 
*Including BRCA1, BRCA2, Li-Fraumeni’s syndromes. Individual may also
include family history of other cancers but not bowel. †Including FAP,
HNPCC, Lynch2 syndromes. Individual may also have family history of other
cancers but not breast. ‡Individual may also include family history of other
cancers but not bowel or breast. §Various cancer sites specified. 
Table 3 Regional variations in cancer genetic activity 
Centre Estimated Estimated  Estimated  Median  Proportion  of 
number† New attendees  Referrals  Follow-ups  waiting time  attendees at 
seen p.a. per m p.a. per m p.a. per m (weeks) low risk 
19 378 353 403 26 58.3% 
11 473 410 236 18 57.9% 
22 113 76 0 7 37.5% 
18 504 336 557 17 8.8% 
16 142 95 32 44 28.6% 
20 63 213 0 50 0.0% 
3 196 105 14 14 33.3% 
21 107 76 32 8 37.5% 
6 200 298 80 29 23.1% 
14 206 286 0 18 10.7% 
8 168 131 16 53 22.2% 
13 239 302 18 18 34.1% 
4 135 204 13 19 33.3% 
10 165 130 52 4 23.1% 
17 264 268 309 22 31.6% 
5 104 166 29 10 29.2% 
1 228 252 11 19 22.9% 
12 85 129 24 21 26.3% 
7 & 15* 298 365 33 20 23.8% 
9 227 300 269 28 20.7% 
2 145 208 41 15 25.0% 
All 183 212 82 19 26.6%
Scotland only 289 278 203 18 32.6% 
*Centres 7 & 15 do not have distinguishable catchment populations. †Centres are arranged in ascending order of
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subjects. Neither the use of questionnaire-based referral systems nor
the availability of specialist cancer genetics staff appeared to affect
waiting time but median waiting time was 5 weeks longer (22
weeks) for the 3 centres that provided screening directly (P< 0.001). 
The proportions of attendees at different risk levels varied signifi-
cantly (P < 0.001), with the proportion at population level risk
ranging from 0 (two centres) to 58%. As GPs referred more individ-
uals at population-risk than did hospital clinicians (29% cf 18%, 
P < 0.001), the variations in casemix between centres are partly
explained by the variations in the source of referrals. Centres with
questionnaire-based referral systems seemed to be seeing the same
proportion of population-risk individuals as other centres. The
same was true for those centres with a dedicated cancer genetics
consultant. 
The proportion of those at elevated risk who were offered
genetic testing varied from 0 (2 Scottish centres) to 80% across
the regions (P < 0.001) but the advice on screening (whether to
initiate, avoid, continue or discontinue) did not differ signifi-
cantly. Testing and screening were no more likely in centres with a
dedicated cancer genetics consultant or in those that provide
screening directly or in those without designated cancer genetics
clinics. ‘Followup’ rates depended on screening strategy. The 3
centres providing mammography directly accounted for two thirds
of all contacts with returning attendees. 
Figures for the 4 Scottish centres combined are presented sepa-
rately as the Scottish service model implies less restrictive referral
criteria. There were almost twice as many referrals and consulta-
tions per million population in Scotland than in the rest of the UK.
There were substantially more population-risk (33% c.f. 26%) and
medium-risk individuals (54% c.f. 49%). The Scottish centres
reported that genetic testing was only available for research
purposes; consequently they reported that genetic testing would
only be discussed with 10% of individuals at medium risk or
above compared with 73% in the rest of the UK. 
DISCUSSION 
Access to cancer genetics services 
All of the UK regional clinical genetics services deal with individ-
uals with a family history of cancer and only 2 of the 22 regions
surveyed did not have designated cancer genetics clinics. Many of
these services have developed intensively over recent years and
service provision compares favourably with that reported for the
USA 4 years earlier (Thompson et al, 1995). 
There is considerable variation in the resources and output of
these services. The numbers of individuals referred were propor-
tionately greater in those regions with a ‘dedicated’ cancer geneti-
cist, direct provision of screening or questionnaire-based referral
systems. Across the UK there was an 8-fold difference in the
number of individuals seen as a proportion of catchment population
and a 13-fold difference in waiting time, suggesting regional
inequity of access. For high-risk families, those with a pattern of
cancer in their family indicating Mendelian inheritance, access to
the clinical genetics service is a greater priority since molecular
testing in this group is more likely to find a genetic mutation. This
would allow individuals at very high risk to be distinguished from
relatives at much lower risk enabling more specific management.
There were too few individuals at high-risk in this sample to effec-
tively analyse regional equity of access for this subgroup. However,
when this group is combined with those at moderate risk there is
strong evidence of regional inequality of access to a specialist
cancer genetics consultant and to genetic testing. There was no
evidence of variation in screening recommendations, however this
is somewhat tautological given that the moderate risk category was
defined in relation to its need for screening. More important in
terms of access is the supply of screening for genetically high-risk
individuals, which in all but three regions is down to the individual
policies of the local screening units and surgical departments. 
A striking feature of the study was that referrals to and consulta-
tions at cancer genetics services overwhelmingly involve women
and in particular those with a family history of breast cancer. This
is partly explained by the prevalence of familial breast cancer in
the population but must also be due to the publicity given to the
breast cancer gene and to the interest in familial cancer shown by
breast clinicians and geneticists over the last 2 decades. However,
even within cancers that are not gender-specific, such as colon
cancer, the number of women attending far outweighs the men. It
is often thought that men generally under-use health services rela-
tive to women but the evidence is unclear (Moynihan, 1998).
Women are sometimes described as the ‘guardians of family
health’. The extent to which relevant genetic risk information will
be passed on to other family members who may be at risk is not
known. We observed, however, that only 35% of women (and 58%
of men) reported that one of the reasons for attending was to find
out the risk of other family members. Ethnic minorities also seem
to be under-represented. The breakdown by gender and cancer site
is remarkably similar to that of France (Sobol et al, 1999) and
comparable with other European services (Hodgson et al, 1999).
However, there was a much larger proportion of affecteds in
France, as a result of cancer genetics being carried out by cancer
centres rather than genetics centres. Cancer genetic activity in
France (2500 new cases each year) was barely a quarter of our
estimate for the UK (Table 1). 
Achievement of service guidelines 
There are few doctors who specialize in cancer genetics. According
to the Harper Report recommendations, there should be at least 27
dedicated cancer genetics consultants for the population covered in
this study, compared with the 11 observed. This situation is unlikely
to change in the near future, as there is little training available for
clinical oncologists to develop expertise in genetic counselling and
no new posts opening up in clinical genetics to meet this need. 
The report also recommended that moderate-risk cases should
usually be managed in the cancer units and primarily high-risk
cases should be referred to the specialist genetics service. The
proportion of population-risk cases attending the regional cancer
genetics service ranged from 0 to 58% implying that the model has
not yet been fully adopted. The extent to which population-level
and moderate-risk individuals are dealt with in cancer units and
primary care must vary between regions. However, we cannot be
sure that individuals encountering these services are being
managed optimally, given that most of these services are not, as
yet, under the guidance of the specialist cancer genetics service, as
envisaged by the Harper Report. 
Evidence from The Netherlands suggests that cancer genetics
practised in primary care may be less than optimal (de Bock et al,
2001), however, research-based initiatives are underway to
educate primary care staff and facilitate liaison between the
genetics services, cancer units and primary care and to reduce
unnecessary referrals. These include the use of computerized risk170 D Wonderling et al 
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assessment (Emery et al, 1999, 2000) or questionnaire-based
family history assessment (Leggatt et al, 1999) by primary care
teams. In several genetics services there are initiatives to train
cancer unit nurses in genetic risk assessment and counselling. This
will be strengthened with the proposed introduction of Macmillan
funded posts into cancer genetic counselling. 
Scotland appears to be closer to meeting the structure of its
planned service model. There are few family history clinics
outside of the regional genetics service. Consequently these
services have more attendees than their English counterparts and
proportionately more population-level and moderate-risk individ-
uals. Of course, around the UK achievement of model guidelines
may have improved since the survey was conducted. 
Appropriateness of service guidelines 
The Scottish Office model emphasizes the importance of a central
referral system for all potential cases of familial cancer and access
to genetic counsellors for individuals at lower levels of risk. This is
a more comprehensive but potentially more costly approach than
that proposed by the Harper Report where population-level risk
individuals are dealt with mainly in primary care and those at
moderately elevated risk in the cancer unit. A recent clinical trial
(Brain et al, 2000) has shown that multi-disciplinary genetics
teams were no more effective than breast surgeons at managing
cases of familial breast cancer, when effectiveness was measured
in terms of psychosocial outcomes. This would suggest that the
Scottish model is unnecessarily reliant on the clinical genetics
service although it may not be possible to generalize the results of
Brain et al’s study to other regions. Furthermore, Brain et al may
have underestimated the extent to which inappropriate resource
allocation occurs when clinical genetics is not utilized. Some
centres in our study were re-evaluating individuals whose risk
has previously been overestimated by nonspecialists. We found
that, across all regions, the geneticists were recommending that
screening be discontinued for 19% of population-level risk indi-
viduals (and be avoided for the rest of this risk group). 
Regardless of which service model is followed, it is important
that there is cohesion between the clinical genetics service, cancer
units and primary care and, at the time of this study, this seems to
be more evident in Scotland than in the rest of the UK. 
Conclusions 
The discovery of genes that cause elevated risk of cancer has lead to
a substantial increase in the number of individuals being identified
as having a ‘genetic disorder’. This has established a workload,
which is beyond the capacity of the UK regional genetics services.
In the short term at least, most of these individuals must be dealt
with by other sectors of the health service but to ensure appropriate
clinical management this should be under the guidance of specialist
cancer geneticists. The lack of cohesion between clinical cancer
genetics and other cancer services is more evident in England and
Wales than in Scotland. Initiatives to disseminate referral and
management guidelines to cancer units and primary care should be
encouraged and adequately resources so that clinical genetics teams
can focus on genetic testing and management of high-risk families. 
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